Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04821622 · ClinicalTrials.gov registry record · Phase 3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
A Phase 3 study of Prostate Cancer, sponsored by Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 599
- Enrollment target
- 20
- Study locations
NCT04821622: Active Phase 3 study of Prostate Cancer, sponsored by Pfizer.
NCT04821622 is a Phase 3 study of Prostate Cancer that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 599 participants, roughly in line with the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target. The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04821622, a Phase 3 study of Prostate Cancer, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 599 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
Primary Outcome
time from the date of randomization to first objective evidence of radiographic progression or death, whichever occurs first
Conditions Studied
Interventions
- DRUG talazoparib plus enzalutamide
- DRUG Placebo plus enzalutamide
Study Locations (20)
Georgia
- Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital - Austell
- Wellstar Cobb Hospital - Austell
- Northwest Georgia Oncology Centers, a Service of Tanner Medical Center Villa Rica - Carrollton
- West Georgia Infusion Center, a Service of Tanner Medical Center Villa Rica - Carrollton
- Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital - Cartersville
- Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital - Douglasville
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital - Marietta
California
- Beverly Hills Cancer Center - Beverly Hills
- Adventist Health Glendale - Glendale
- VA Long Beach Healthcare System - Long Beach
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham - Birmingham
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
- Washington Cancer Institute at MedStar Washington Hospital Center - Washington D.C.
Florida
- AdventHealth Medical Group Hematology and Oncology - Orlando
- Investigational Drug Services, Advent Health Orlando - Orlando
Illinois
- Comprehensive Urologic Care, SC - Lake Barrington
- Mid-Illinois Hematology & Oncology Associates, Ltd - Normal
Arizona
- Arizona Institute of Urology, PLLC - Tucson
Connecticut
- Yale-New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2021-05-12 |
| Est. Completion | 2027-08-28 |
| Phase | Phase 3 |
What the registry record for NCT04821622 still lists
NCT04821622 is an interventional study that assigns participants to a tested intervention. The registered 599 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which talazoparib plus enzalutamide is the first listed.
NCT04821622 names 20 study sites across 8 states, led by Georgia, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04821622 about?
NCT04821622 is a clinical study titled "Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC". The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
What is the current status of trial NCT04821622?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 599 participants. The study started on 2021-05-12. Estimated completion is 2027-08-28.
What conditions does trial NCT04821622 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT04821622?
The interventions under investigation include: talazoparib plus enzalutamide (DRUG), Placebo plus enzalutamide (DRUG).
Who is sponsoring clinical trial NCT04821622?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04821622 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04821622's enrollment target sits among peer trials
599 98th of 735 higher than 638 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06875973 · 599 participants · Phase 3
Pelacarsen Roll-over Extension Program
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI